Department of Gastroenterology, Hepatology & Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany.
Expert Rev Anticancer Ther. 2021 Jun;21(6):621-628. doi: 10.1080/14737140.2021.1882855. Epub 2021 May 4.
: Hepatocellular carcinoma (HCC) is one of the most common and deadliest cancers worldwide. In recent years, several drugs have been approved in first- and second-line setting. Currently, several phase-III trials are ongoing with combinations of checkpoint inhibitors, tyrosine kinase inhibitors (TKI) and anti-angiogenic antibodies, which will most likely increase therapeutic options in frontline therapy in the near future.: This review summarizes the standard of care in first-line systemic therapy for patients with advanced HCC and provides an outlook on the most promising combinations currently tested in prospective trials.: The recent approval of novel substances has substantially changed the field of palliative treatment strategies in patients with advanced HCC. Immuno-oncology (IO)-based combination therapies will become the next standard of care in frontline HCC. The potent anti-tumor efficacy and good tolerability of these therapies will increase the use of upfront systemic therapy in patients with intermediate stage HCC.
肝细胞癌（HCC）是全球最常见和最致命的癌症之一。近年来，已有几种药物在一线和二线治疗中获得批准。目前，正在进行几项与检查点抑制剂、酪氨酸激酶抑制剂（TKI）和抗血管生成抗体联合使用的 III 期临床试验，这些试验很可能在不久的将来增加一线治疗的治疗选择。
本文综述了晚期 HCC 患者一线全身治疗的标准治疗方法，并展望了目前正在前瞻性试验中测试的最有前途的联合治疗方案。
新型药物的最近批准极大地改变了晚期 HCC 患者姑息治疗策略的领域。基于免疫肿瘤学（IO）的联合疗法将成为 HCC 一线治疗的下一个标准。这些疗法具有强大的抗肿瘤疗效和良好的耐受性，将增加中危 HCC 患者的一线系统治疗的使用。
